Entera Bio appoints former Pfizer exec Geno J. Germano as Chairman, replacing Gerald Lieberman

Entera Bio Ltd.

Geno Germano appointed Class III director and Chairman of the Board effective February 4, 2026.
Gerald Lieberman resigned as Chairman and Director effective Feb 4, 2026, no disagreement.
Germano led Pfizer's $14B Global Innovative Pharma business as Group President until 2016.
Entera plans Phase 3 registrational study for EB613 (osteoporosis) and first-in-human for Long-Acting Oral PTH (hypoparathyroidism) in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.